700 related articles for article (PubMed ID: 26260259)
1. Differential antitumor effects of vitamin D analogues on colorectal carcinoma in culture.
Wierzbicka JM; Binek A; Ahrends T; Nowacka JD; Szydłowska A; Turczyk Ł; Wąsiewicz T; Wierzbicki PM; Sądej R; Tuckey RC; Slominski AT; Chybicki J; Adrych K; Kmieć Z; Żmijewski MA
Int J Oncol; 2015 Sep; 47(3):1084-96. PubMed ID: 26260259
[TBL] [Abstract][Full Text] [Related]
2. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative Activity of Non-Calcemic Vitamin D Analogs on Human Melanoma Lines in Relation to VDR and PDIA3 Receptors.
Wasiewicz T; Piotrowska A; Wierzbicka J; Slominski AT; Zmijewski MA
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30200275
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of vitamin D analogs on hamster and mouse melanoma cell lines in relation to melanin pigmentation.
Wasiewicz T; Szyszka P; Cichorek M; Janjetovic Z; Tuckey RC; Slominski AT; Zmijewski MA
Int J Mol Sci; 2015 Mar; 16(4):6645-67. PubMed ID: 25811927
[TBL] [Abstract][Full Text] [Related]
5. A High-Calcium and Phosphate Rescue Diet and VDR-Expressing Transgenes Normalize Serum Vitamin D Metabolite Profiles and Renal Cyp27b1 and Cyp24a1 Expression in VDR Null Mice.
Kaufmann M; Lee SM; Pike JW; Jones G
Endocrinology; 2015 Dec; 156(12):4388-97. PubMed ID: 26441239
[TBL] [Abstract][Full Text] [Related]
6. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5.
Mehta RG; Moriarty RM; Mehta RR; Penmasta R; Lazzaro G; Constantinou A; Guo L
J Natl Cancer Inst; 1997 Feb; 89(3):212-8. PubMed ID: 9017001
[TBL] [Abstract][Full Text] [Related]
7. Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells.
Munetsuna E; Kawanami R; Nishikawa M; Ikeda S; Nakabayashi S; Yasuda K; Ohta M; Kamakura M; Ikushiro S; Sakaki T
Mol Cell Endocrinol; 2014 Feb; 382(2):960-70. PubMed ID: 24291609
[TBL] [Abstract][Full Text] [Related]
8. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells.
Reichrath J; Rech M; Moeini M; Meese E; Tilgen W; Seifert M
Cancer Biol Ther; 2007 Jan; 6(1):48-55. PubMed ID: 17172823
[TBL] [Abstract][Full Text] [Related]
9. Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse.
Masuda S; Byford V; Arabian A; Sakai Y; Demay MB; St-Arnaud R; Jones G
Endocrinology; 2005 Feb; 146(2):825-34. PubMed ID: 15498883
[TBL] [Abstract][Full Text] [Related]
10. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.
Chen TC; Holick MF; Lokeshwar BL; Burnstein KL; Schwartz GG
Recent Results Cancer Res; 2003; 164():273-88. PubMed ID: 12899529
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor expression and associated gene signature in tumour stromal fibroblasts predict clinical outcome in colorectal cancer.
Ferrer-Mayorga G; Gómez-López G; Barbáchano A; Fernández-Barral A; Peña C; Pisano DG; Cantero R; Rojo F; Muñoz A; Larriba MJ
Gut; 2017 Aug; 66(8):1449-1462. PubMed ID: 27053631
[TBL] [Abstract][Full Text] [Related]
13. 25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer and use of non-1alpha-hydroxylated vitamin D analogue.
Segersten U; Holm PK; Björklund P; Hessman O; Nordgren H; Binderup L; Akerström G; Hellman P; Westin G
Breast Cancer Res; 2005; 7(6):R980-6. PubMed ID: 16280049
[TBL] [Abstract][Full Text] [Related]
14. Temporal changes in tissue 1α,25-dihydroxyvitamin D3, vitamin D receptor target genes, and calcium and PTH levels after 1,25(OH)2D3 treatment in mice.
Chow EC; Quach HP; Vieth R; Pang KS
Am J Physiol Endocrinol Metab; 2013 May; 304(9):E977-89. PubMed ID: 23482451
[TBL] [Abstract][Full Text] [Related]
15. 25(OH)D3 and 1,25(OH)2D3 serum concentration and breast tissue expression of 1alpha-hydroxylase, 24-hydroxylase and Vitamin D receptor in women with and without breast cancer.
de Lyra EC; da Silva IA; Katayama ML; Brentani MM; Nonogaki S; Góes JC; Folgueira MA
J Steroid Biochem Mol Biol; 2006 Aug; 100(4-5):184-92. PubMed ID: 16828283
[TBL] [Abstract][Full Text] [Related]
16. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
17. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells.
Barreto AM; Schwartz GG; Woodruff R; Cramer SD
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):265-70. PubMed ID: 10750664
[TBL] [Abstract][Full Text] [Related]
18. Substitution at carbon 2 of 19-nor-1α,25-dihydroxyvitamin D3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells.
Iglesias-Gato D; Zheng S; Flanagan JN; Jiang L; Kittaka A; Sakaki T; Yamamoto K; Itoh T; Lebrasseur NK; Norstedt G; Chen TC
J Steroid Biochem Mol Biol; 2011 Nov; 127(3-5):269-75. PubMed ID: 21911059
[TBL] [Abstract][Full Text] [Related]
19. Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid.
Kane KF; Langman MJ; Williams GR
Cancer Res; 1996 Feb; 56(3):623-32. PubMed ID: 8564982
[TBL] [Abstract][Full Text] [Related]
20. CYP24A1 Inhibition Facilitates the Antiproliferative Effect of 1,25(OH)
Sun H; Jiang C; Cong L; Wu N; Wang X; Hao M; Liu T; Wang L; Liu Y; Cong X
DNA Cell Biol; 2018 Sep; 37(9):742-749. PubMed ID: 30052060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
